TY  - ADVS
AU  - Schoeberl,Birgit
TI  - A systems biology approach to oncology drug development: clinical testing of biomarkers for the anti-ErbB3 antibody MM-121 
T2  - Systems biology,
PY  - 2015///
CY  - London
PB  - Henry Stewart Talks
KW  - Antineoplastic agents
KW  - Development
KW  - Computational biology
KW  - Drug development
KW  - Pharmaceutical technology
KW  - Data processing
KW  - Antibodies, Monoclonal
KW  - pharmacology
KW  - Antineoplastic Agents
KW  - Cell Line, Tumor
KW  - Drug Design
KW  - Drug Discovery
KW  - Genes, erbB
KW  - Ligands
KW  - Neoplasms
KW  - drug therapy
KW  - Receptor, ErbB-3
KW  - antagonists & inhibitors
KW  - immunology
KW  - Systems Biology
KW  - Technology, Pharmaceutical
KW  - methods
N1  - Animated audio-visual presentation with synchronized narration; Title from title frames; Contents: Oncology drug development -- Network biology -- The HRG family of ligands -- The ErbB pathway -- MM-121 mechanism of action -- Data from in-vitro and iv-vivo experiments using MM-121 -- Timeline of MM-121: 2003-2015; Access restricted to subscribers
UR  - https://hstalks.com/bs/3104/
UR  - https://hstalks.com/bs/p/876/
ER  -